Skip to main content
. 2020 May 5;7(3):179–189. doi: 10.1007/s40801-020-00191-x

Fig. 1.

Fig. 1

Duration of therapy in TOUR patients with bacteremia or endocarditis (N = 151). Due to rounding, percentages add up to 99.9%; however, all patients with bacteremia or endocarditis are represented. TLV telavancin, TOUR telavancin observational use registry